Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Collaborators:
Janssen Scientific Affairs, LLC
OHSU Knight Cancer Institute
Rutgers Cancer Institute of New Jersey
NorthShore University HealthSystem
Duke University
Feinberg School of Medicine, Northwestern University
Sidney Kimmel Comprehensive Cancer Center
University of North Carolina
Wayne State University
Perlmutter New York University Cancer Center
Weill Medical College of Cornell University
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01751451
First received: December 14, 2012
Last updated: September 23, 2014
Last verified: September 2014

December 14, 2012
September 23, 2014
December 2012
October 2015   (final data collection date for primary outcome measure)
  • progression-free survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
    defined as an undetectable PSA (using a routine non-ultrasensitive PSA assay) with non-castrate level of testosterone (>150 ng/dL) at 18 months from the time of treatment initiation (PSA0).
  • Soft tissue complete response [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    In addition to an undetectable PSA, any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm (Complete Response per RECIST) in order to meet the criteria for PFS. Outcome in subjects who develop radiographically evident metastatic disease while on study will be considered treatment failures independent of their respective PSA values.
progression-free survival (PFS) [ Time Frame: 18 months ] [ Designated as safety issue: No ]
PFS is defined as an undetectable (≤0.05 ng/mL) PSA with a non-castrate level of testosterone (>150 ng/dL). Pathological lymph nodes (whether target or non-target) must also have reduction in short axis to <10 mm (Complete Response per RECIST) in order to meet the criteria for PFS.
Complete list of historical versions of study NCT01751451 on ClinicalTrials.gov Archive Site
  • PSA response rate [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    The percentage of patients with a non-castrate level of testosterone (>150 ng/dL) and an undetectable PSA at 8 months from PSA0 will be measured.
  • overall quality of life [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    with particular attention to libido, potency, anxiety, depression, hot flashes, and fatigue. Effects of each arm on health-related quality of life will be assessed via PRO Survey (Appendix C) completed on paper by the patient at the following study visits: Up to 30 Days Prior to Randomization, each Day 1 of Treatment Cycle, End of Treatment, and each Post-Treatment Follow-up.Effects of each arm on quality of life,
  • non-hematologic adverse events [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Safety will be evaluated according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations and clinical laboratory tests throughout the conduct of the study.
  • Testosterone and luteinizing hormone (LH) recovery rates [ Time Frame: 8 -10 months ] [ Designated as safety issue: No ]
    Testosterone and LH recovery rates will be measured at 8 months from the start of randomization and at each month of the 10 month follow up period.
  • Correlative tissue analysis [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Tissue samples will be utilized for morphologic assessment, percent tumor involvement (if applicable), and immunohistochemistry. The immunohistochemical markers assessed may be AR, PTEN, PSMA, fatty acid synthase (FASN), phospho-AMPK, phospho-ACC, phospho-S6 kinase, phospho-Akt for the assessment of the AMPK, lipid synthesis, mTOR pathways, and immunological markers.
  • PSA response rate [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    Percentage of patients with an undetectable PSA at 8 months from PSA 0. Treatment response defined as achieving and maintaining an undetectable PSA level (≤0.05 ng/mL) with a non-castrate level of testosterone (>150 ng/dL) will be assessed at 8 months from PSA0.
  • overall quality of life [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    with particular attention to libido, potency, anxiety, depression, hot flashes, and fatigue. Effects of each arm on health-related quality of life will be assessed via PRO Survey (Appendix C) completed on paper by the patient at the following study visits: Up to 30 Days Prior to Randomization, each Day 1 of Treatment Cycle, End of Treatment, and each Post-Treatment Follow-up.Effects of each arm on quality of life,
  • non-hematologic adverse events [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    Safety will be evaluated according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations and clinical laboratory tests throughout the conduct of the study.
  • Testosterone and leuteinizing hormone (LH) recovery rates [ Time Frame: 8 months ] [ Designated as safety issue: No ]
    Testosterone and LH recovery rates will be measured at 8 months from the start of randomization.
  • Correlative tissue analysis [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    Tissue samples will be utilized for morphologic assessment, percent tumor involvement (if applicable), and immunohistochemistry. The immunohistochemical markers assessed may be AR, PTEN, PSMA, fatty acid synthase (FASN), phospho-AMPK, phospho-ACC, phospho-S6 kinase, phospho-Akt for the assessment of the AMPK, lipid synthesis, mTOR pathways, and immunological markers.
Not Provided
Not Provided
 
3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy
A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

In April 2011, the United States Food and Drug Administration (FDA) approved the oral drug abiraterone acetate (Zytiga ®) in combination with prednisone (a steroid) to treat patients with metastatic castration-resistant prostate cancer who have received prior docetaxel (chemotherapy). In December 2012, the FDA approved Zytiga ® in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who have not received prior chemotherapy. Degarelix (Firmagon ®), a testosterone lowering agent given as a monthly injection, is FDA approved for the treatment of patients with advanced prostate cancer. The purpose of this study is to evaluate abiraterone acetate and prednisone in combination with degarelix as a possible treatment for PSA recurrent prostate cancer as compared to abiraterone acetate alone and degarelix alone. This will be the first time these drugs will be used together.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostate Cancer
  • Drug: Abiraterone acetate
    Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
  • Drug: Abiraterone acetate plus degarelix
    Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
  • Drug: Degarelix
    Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
  • Experimental: Abiraterone acetate

    Group 1

    • Abiraterone acetate 1000 mg daily x 8 months
    • Prednisone 5 mg once daily x 8 months
    Intervention: Drug: Abiraterone acetate
  • Experimental: Abiraterone acetate and Degarelix

    Group 2

    Abiraterone acetate 1000 mg daily x 8 months

    • Prednisone 5 mg once daily x 8 months
    • Degarelix subcutaneous depot injection q 1 month x 8 months
    Intervention: Drug: Abiraterone acetate plus degarelix
  • Experimental: Degarelix

    Group 3

    • Degarelix subcutaneous depot injection q 1 month x 8 months

    Intervention: Drug: Degarelix
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
October 2015
October 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willing and able to provide written informed consent and Authorization for Use and Release of Health and Research Study Information (HIPAA authorization) NOTE: HIPAA authorization may be either included in the informed consent or obtained separately.
  • Male aged 18 years and above
  • Patients must have undergone local treatment via radical prostatectomy
  • Patients who have received primary radiation therapy followed by a salvage radical prostatectomy are eligible.
  • Patients who have had post-operative radiation therapy for presumed locally recurrent disease are eligible
  • Histologically confirmed prostate cancer (per standards at Institution of participant registration) currently with progressive disease, defined as:
  • Rising PSA (50% or more increase to a level of 1 ng/mL or more, based on at least 3 PSA determinations obtained at least 1 week apart). The 50% rise in PSA is across the 3 determinations, and these determinations do not need to be sequential AND
  • PSADT ≤ 9 months as calculated according to the Memorial Sloan-Kettering Cancer Center nomogram (http://www.mskcc.org/mskcc/html/10088.cfm) OR
  • Rising PSA as defined above AND
  • Metastatic disease limited to the presence of pelvic and/or retroperitoneal nodes < 2 cm in short axis.
  • Patients must have a serum testosterone of 150 ng/dL or greater
  • ECOG performance status of ≤ 2 (Appendix A)
  • Adequate bone marrow, hepatic, and renal function, as evidenced within 14 days prior to treatment initiation by:
  • Absolute neutrophil count (ANC) ≥ 1500/mm3
  • Platelet count ≥ 100,000/mm3
  • Hemoglobin ≥ 9 g/dL without need for hematopoietic growth factor or transfusion support within 30 days prior to treatment initiation
  • Aspartate aminotransferase (AST) ≤ 1.5 times the upper limit of the normal range (x ULN)
  • Alanine aminotransferase (ALT) ≤ 1.5 x ULN
  • Total bilirubin ≤ 1.5 x ULN
  • Serum creatinine of ≤ 1.5 mg/dl or Calculated creatinine clearance of ≥ 60 mL/min
  • Serum albumin ≥ 3.0 g/dL
  • Serum potassium ≥ 3.5 mEq/L
  • Prothrombin time (PT) ≤ 1.5 x ULN (or international normalized ratio [INR] ≤ 1.3) unless the patient is receiving anticoagulant therapy
  • Partial thromboplastin time (PTT) ≤ 1.5 x ULN unless the patient is receiving anticoagulant therapy At least 4 weeks and recovery to Grade 0-1 from reversible effects of prior surgery (i.e., incisional pain, wound drainage)
  • Able to swallow the study drug whole as a tablet
  • Willing to take abiraterone acetate on an empty stomach; no food should be consumed at least two hours before and for at least one hour after the dose of abiraterone acetate is taken
  • Patients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator during the study and for 1 week after last dose of abiraterone acetate.

Exclusion Criteria:

  • Prior cytotoxic chemotherapy or biologic therapy for prostate cancer
  • More than 8 months of prior hormonal therapy (e.g., gonadotropin-releasing hormone analogs, megestrol acetate, or Casodex) Note: Patients who have been on prior hormonal therapy must wait at least 1 year after the drug is fully metabolized to start treatment on protocol.
  • Prior ketoconazole, abiraterone acetate, or enzalutamide for the treatment of prostate cancer.
  • Known brain metastasis or evidence of metastatic disease by CT scan, physical exam, or bone scan within 4 weeks of registration
  • Patients with equivocal uptake on a bone scan that in the clinician's opinion do not definitively constitute metastatic disease are eligible
  • Currently active second malignancy

Significant medical condition other than cancer, that would prevent consistent and compliant participation in the study that would, in the opinion of the investigator, make this protocol unreasonably hazardous including but not limited to:

  • Active infection or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated
  • History of gastrointestinal disorders (medical disorders or extensive surgery) that may interfere with the absorption of the study agents
  • Uncontrolled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 95 mmHg); patients with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
  • Active or symptomatic viral hepatitis or chronic liver disease
  • History of pituitary or adrenal dysfunction
  • Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or New York Heart Association (NYHA) Class III or IV heart disease or cardiac ejection fraction measurement of < 50 % at baseline
  • Atrial fibrillation, or other cardiac arrhythmia requiring medical therapy
  • Uncontrolled diabetes mellitus
  • Active psychiatric condition Use of any prohibited concomitant medications (Section 5.5) within 30 days prior to Cycle 1, Day 1
  • Pre-existing condition that warrants long-term corticosteroid use in excess of study dose
  • Grade > 2 treatment-related toxicity from prior therapy
  • Known allergies, hypersensitivity or intolerance to abiraterone acetate, prednisone or degarelix
  • Administration of an investigational therapeutic within 30 days of Cycle 1, Day1
  • Any condition which, in the opinion of the investigator, would preclude participation in this trial
Male
18 Years and older
No
Contact: Howard I Scher, MD 646-422-4330
Contact: Michael Morris, MD 646-422-4469
United States
 
NCT01751451
12-187
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
  • Janssen Scientific Affairs, LLC
  • OHSU Knight Cancer Institute
  • Rutgers Cancer Institute of New Jersey
  • NorthShore University HealthSystem
  • Duke University
  • Feinberg School of Medicine, Northwestern University
  • Sidney Kimmel Comprehensive Cancer Center
  • University of North Carolina
  • Wayne State University
  • Perlmutter New York University Cancer Center
  • Weill Medical College of Cornell University
  • Ferring Pharmaceuticals
Principal Investigator: Howard I Scher, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP